Jim Cassidy, MD, PhD

Articles by Jim Cassidy, MD, PhD

Jim Cassidy, MD, PhD (Credit: SpringWorks Therapeutics)

Potential of Advancing Neurofibromatosis Care With Investigational Mirdametinib

ByJim Cassidy, MD, PhD,Isabella Ciccone, MPH

September 4th 2024

Jim Cassidy, MD, PhD, chief medical officer at SpringWorks Therapeutics, talked about how the prioritization of mirdametinib, a promising treatment for both adult and pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas.

Latest Updated Articles

FDA Approves Lecanemab Autoinjector, Marking First At-Home Treatment for Alzheimer Disease
Published: August 29th 2025 | Updated: September 2nd 2025
Indirect Comparison Study Hints at Lower ARIA and ICH-Related Mortality Risk in Lecanemab Over Donanemab
Published: July 28th 2025 | Updated: July 30th 2025
Observed Differences in PIRA Definition Call for More Standardized Agreement on Term
Published: May 14th 2025 | Updated: May 16th 2025
Serum Neurofilament Light Chain Limited in Predicting MOGAD Attacks but Correlates With Attack Severity
Published: May 12th 2025 | Updated: May 13th 2025
FDA Approves Diazoxide Choline Extended-Release Tablets for Hyperphagia in Prader-Willi Syndrome
Published: March 27th 2025 | Updated: March 28th 2025
BTK Inhibitor Tolebrutinib Shows Greater Effectiveness in Multiple Sclerosis with Higher Paramagnetic Rim Lesion Counts
Published: March 4th 2025 | Updated: March 19th 2025

Trending on NeurologyLive

Stem Cells of Secondary Progressive Multiple Sclerosis Drive Increased Proinflammatory T-Cell Activity

EMA Approves Semaglutide as First GLP-1 RA for Cardiovascular, Stroke-Related Benefits

Postmortem Analysis Reveals Distinct Patterns of Aquaporin-4 in Parkinson Disease and Multiple System Atrophy

Perispinal Etanercept Shows No Efficacy in Treating Chronic Stroke

Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update

© 2025 MJH Life Sciences^®

All rights reserved.